Dynavax (DVAX) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Dynavax Revenue Highlights

Latest Revenue (Y)

$277.25M

Latest Revenue (Q)

$79.34M

Main Segment (Y)

H E P L I S A V B

Main Geography (Y)

UNITED STATES

Dynavax Revenue by Period

Dynavax Revenue by Year

Date	Revenue	Change
2024-12-31	$277.25M	19.36%
2023-12-31	$232.28M	-67.86%
2022-12-31	$722.68M	64.45%
2021-12-31	$439.44M	844.00%
2020-12-31	$46.55M	32.18%
2019-12-31	$35.22M	329.60%
2018-12-31	$8.20M	2407.03%
2017-12-31	$327.00K	-97.04%
2016-12-31	$11.04M	172.67%
2015-12-31	$4.05M	-63.29%
2014-12-31	$11.03M	-1.95%
2013-12-31	$11.25M	15.82%
2012-12-31	$9.71M	-55.06%
2011-12-31	$21.61M	-9.75%
2010-12-31	$23.95M	-40.60%
2009-12-31	$40.32M	8.69%
2008-12-31	$37.09M	163.21%
2007-12-31	$14.09M	190.76%
2006-12-31	$4.85M	-66.93%
2005-12-31	$14.65M	-1.06%
2004-12-31	$14.81M	1693.22%
2003-12-31	$826.00K	-42.12%
2002-12-31	$1.43M	-39.51%
2001-12-31	$2.36M	100.00%
2000-12-31	-	-

Dynavax generated $277.25M in revenue during NA 2024, up 19.36% compared to the previous quarter, and up 787.21% compared to the same period a year ago.

Dynavax Revenue by Quarter

Date	Revenue	Change
2024-09-30	$79.34M	7.52%
2024-06-30	$73.80M	45.29%
2024-03-31	$50.79M	-8.64%
2023-12-31	$55.60M	-20.02%
2023-09-30	$69.51M	15.38%
2023-06-30	$60.25M	28.39%
2023-03-31	$46.92M	-74.57%
2022-12-31	$184.49M	9.99%
2022-09-30	$167.74M	-34.60%
2022-06-30	$256.46M	124.98%
2022-03-31	$113.99M	-41.56%
2021-12-31	$195.07M	80.17%
2021-09-30	$108.27M	105.19%
2021-06-30	$52.77M	-36.68%
2021-03-31	$83.33M	326.27%
2020-12-31	$19.55M	45.74%
2020-09-30	$13.41M	402.77%
2020-06-30	$2.67M	-75.57%
2020-03-31	$10.92M	3.30%
2019-12-31	$10.57M	-0.05%
2019-09-30	$10.57M	27.39%
2019-06-30	$8.30M	43.79%
2019-03-31	$5.77M	8.56%
2018-12-31	$5.32M	264.00%
2018-09-30	$1.46M	16.51%
2018-06-30	$1.25M	660.00%
2018-03-31	$165.00K	685.71%
2017-12-31	$21.00K	-60.38%
2017-09-30	$53.00K	-49.52%
2017-06-30	$105.00K	-29.05%
2017-03-31	$148.00K	-97.97%
2016-12-31	$7.29M	4401.23%
2016-09-30	$162.00K	-93.88%
2016-06-30	$2.65M	181.00%
2016-03-31	$942.00K	37.52%
2015-12-31	$685.00K	-42.34%
2015-09-30	$1.19M	-23.35%
2015-06-30	$1.55M	147.21%
2015-03-31	$627.00K	-72.46%
2014-12-31	$2.28M	3.08%
2014-09-30	$2.21M	-27.53%
2014-06-30	$3.05M	-12.86%
2014-03-31	$3.50M	22.87%
2013-12-31	$2.85M	-2.73%
2013-09-30	$2.93M	-13.71%
2013-06-30	$3.39M	62.69%
2013-03-31	$2.08M	15.45%
2012-12-31	$1.81M	-37.16%
2012-09-30	$2.87M	7.08%
2012-06-30	$2.68M	14.21%
2012-03-31	$2.35M	-79.43%
2011-12-31	$11.43M	873.34%
2011-09-30	$1.17M	-83.85%
2011-06-30	$7.27M	316.80%
2011-03-31	$1.74M	-1.25%
2010-12-31	$1.77M	-84.84%
2010-09-30	$11.65M	431.68%
2010-06-30	$2.19M	-73.74%
2010-03-31	$8.34M	281.18%
2009-12-31	$2.19M	-24.54%
2009-09-30	$2.90M	-81.74%
2009-06-30	$15.88M	-17.89%
2009-03-31	$19.34M	61.94%
2008-12-31	$11.95M	34.87%
2008-09-30	$8.86M	-11.23%
2008-06-30	$9.98M	58.03%
2008-03-31	$6.31M	-32.07%
2007-12-31	$9.29M	-

Dynavax generated $79.34M in revenue during Q3 2024, up 7.52% compared to the previous quarter, and up 131.70% compared to the same period a year ago.

Dynavax Revenue Breakdown

Dynavax Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 24	Dec 23	Dec 21	Dec 20	Dec 19
H E P L I S A V B	$268.43M	$213.29M	$800.00K	-	-
Other Revenue	$8.82M	$18.99M	$432.00K	-	-
Product	$268.43M	$213.29M	$39.31M	$34.64M	-
Cp G1018	-	-	$38.21M	$3.28M	-
Collaboration Revenue	-	-	-	-	$143.00K

Dynavax's latest annual revenue breakdown by segment (product or service), as of Dec 24: H E P L I S A V B (49.19%), Product (49.19%), and Other Revenue (1.62%).

Quarterly Revenue by Product

Product/Service	Dec 24	Sep 24	Mar 24	Dec 23	Sep 23	Dec 22	Sep 22	Jun 22	Mar 22	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
Product	$141.24M	$79.34M	$47.84M	$150.98M	$62.32M	$82.89M	$13.11M	$13.28M	$2.40M	$10.51M	$10.56M	$10.16M	$8.30M	$5.63M	-	-	-	-	-	-
H E P L I S A V B	$141.24M	$79.34M	$47.84M	$150.98M	$62.32M	$700.00K	$11.51M	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Revenue	$4.59M	$1.28M	$2.94M	$11.79M	$7.20M	$263.00K	$405.00K	$-131.00K	$417.00K	-	-	-	-	-	-	-	-	-	-	-
Cp G1018	-	-	-	-	-	$87.04M	$99.07M	$126.37M	$37.03M	$1.16M	$37.05M	$74.58M	$1.60M	-	-	-	-	-	-	-
Coalition For Epidemic Preparedness Innovations	-	-	-	-	-	-	-	-	$400.00K	$68.00M	$107.00M	-	-	-	-	-	-	-	-	-
Collaboration Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$100.00K	$146.00K	-	-	-	-	-

Dynavax's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Product (49.20%), H E P L I S A V B (49.20%), and Other Revenue (1.60%).

Dynavax Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 24	Dec 23	Dec 22	Dec 21
Non-US	$3.63M	$1.34M	$588.65M	$428.00K
UNITED STATES	$273.62M	$230.94M	$8.77M	$1.92M

Dynavax's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (98.69%), and Non-US (1.31%).

Quarterly Revenue by Country

Country	Dec 24	Sep 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
UNITED STATES	$143.51M	$80.61M	$49.50M	$154.15M	$69.51M	$3.81M	$3.47M	$2.21M	$3.88M	$1.08M	$1.61M	$455.00K	$23.91M	$260.00K
Non-US	$2.32M	$22.00K	$1.29M	-	-	-	$147.24M	$126.31M	$223.58M	$59.00K	$74.00K	-	-	-
Non Us	-	-	-	-	-	-	-	-	-	-	-	-	$84.36M	$39.08M

Dynavax's latest quarterly revenue breakdown by geography, as of Dec 24: UNITED STATES (98.41%), and Non-US (1.59%).

Dynavax Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
NBIX	Neurocrine Biosciences	$2.36B	$622.10M
ALKS	Alkermes	$1.56B	$378.14M
LNTH	Lantheus	$1.53B	$378.73M
EBS	Emergent BioSolutions	$1.04B	$254.70M
AMPH	Amphastar Pharmaceuticals	$712.81M	$188.82M
PCRX	Pacira BioSciences	$700.97M	$168.57M
ITCI	Intra-Cellular Therapies	$680.85M	$175.38M
COLL	Collegium Pharmaceutical	$631.45M	$159.30M
ANIP	ANI Pharmaceuticals	$614.38M	$148.33M
IRWD	Ironwood Pharmaceuticals	$351.41M	$91.59M
DVAX	Dynavax	$277.25M	$79.34M
AQST	Aquestive Therapeutics	$57.56M	$13.54M
DRRX	DURECT	$2.03M	$1.56M

DVAX Revenue FAQ

What is Dynavax’s yearly revenue?

Dynavax's yearly revenue for 2024 was $277.25M, representing an increase of 19.36% compared to 2023. The company's yearly revenue for 2023 was $232.28M, representing a decrease of -67.86% compared to 2022. DVAX's yearly revenue for 2022 was $722.68M, representing an increase of 64.45% compared to 2021.

What is Dynavax’s quarterly revenue?

Dynavax's quarterly revenue for Q3 2024 was $79.34M, a 7.52% increase from the previous quarter (Q2 2024), and a 14.14% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $73.8M, a 45.29% increase from the previous quarter (Q1 2024), and a 22.48% increase year-over-year (Q2 2023). DVAX's quarterly revenue for Q1 2024 was $50.79M, a -8.64% decrease from the previous quarter (Q4 2023), and a 8.24% increase year-over-year (Q1 2023).

What is Dynavax’s revenue growth rate?

Dynavax's revenue growth rate for the last 3 years (2022-2024) was -61.64%, and for the last 5 years (2020-2024) was 495.57%.

What are Dynavax’s revenue streams?

Dynavax's revenue streams in c 24 are H E P L I S A V B, Other Revenue, and Product. H E P L I S A V B generated $268.43M in revenue, accounting 49.19% of the company's total revenue, up 25.85% year-over-year. Other Revenue generated $8.82M in revenue, accounting 1.62% of the company's total revenue, down -53.57% year-over-year. Product generated $268.43M in revenue, accounting 49.19% of the company's total revenue, up 25.85% year-over-year.

What is Dynavax’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Dynavax was H E P L I S A V B. This segment made a revenue of $268.43M, representing 49.19% of the company's total revenue.